Public versus Private Drug Insurance and Outcomes of Patients Requiring Biologic Therapies for Inflammatory Bowel Disease

Table 5

Poisson regression model for IBD-related ED visits.

Characteristic	Unadjusted IRR (95% CI)	Adjusted IRR (95% CI)
Type of drug coverage
Private	ref	ref
Public	2.67 (1.57–4.55)	2.42 (1.43–4.08)
Age	0.99 (0.97–1.01)	0.99 (0.97–1.01)
Age at IBD diagnosis	0.99 (0.96–1.02)	0.99 (0.96–1.03)
Sex
Male	ref	ref
Female	1.87 (1.07–3.26)	1.83 (1.03–3.27)
IBD subtype
Crohn’s disease	ref	ref
Ulcerative colitis	0.63 (0.32–1.24)	0.69 (0.35–1.36)
Immunomodulator use	2.30 (1.29–4.09)	1.87 (1.07–3.27)
Steroid dependent or refractory	1.59 (0.93–2.70)	1.48 (0.90–2.45)
Aggressive IBD phenotype	0.75 (0.43–1.30)	0.59 (0.20–1.80)
Median neighborhood income
1st quintile	ref	ref
2nd quintile	0.75 (0.30–1.85)	0.76 (0.35–1.65)
3rd quintile	0.57 (0.24–1.35)	0.64 (0.30–1.38)
4th quintile	0.35 (0.12–1.00)	0.43 (0.17–1.13)
5th quintile	0.81 (0.35–1.90)	0.88 (0.40–1.94)